Hepatic Tumor Clinical Pipeline | 75+ Companies Driving the Next Generation of Treatment Innovations

The hepatic tumor market is rapidly advancing, fueled by groundbreaking research and innovative therapies from companies such as Genmab/Janssen Biotech, Bio-Thera Solutions, and Ocuphire Pharma. These industry pioneers are transforming treatment strategies and redefining the future of hepatic tumor care, bringing new hope to patients worldwide.

DelveInsight's 'Hepatic Tumor Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Hepatic Tumor therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hepatic Tumor pipeline domain.

For emerging Hepatic Tumor drugs, the Hepatic Tumor pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Hepatic Tumor Pipeline Report
• DelveInsight's Hepatic Tumor Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline drugs for Hepatic Tumor treatment.
• The leading Hepatic Tumor companies include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics., and others are evaluating their lead assets to improve the Hepatic Tumor treatment landscape.
• Key Hepatic Tumor pipeline therapies in various stages of development include Namodenoson, MTL CEBPA, Amivantamab, Fostroxacitabine bralpamide, ETN101, and others.
• In February 2025, RZ-001, an RNA substitution enzyme-based cancer gene therapy, received FDA fast track designation for hepatocellular carcinoma (HCC), according to Rznomics Inc.
• In February 2024, the FDA granted Fast Track designation to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist, as a potential treatment for patients with hepatocellular carcinoma (HCC). This follows the orphan drug designation granted to amezalpat for HCC in January.
• In January 2025, Tempest Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist, for the treatment of hepatocellular carcinoma (HCC).

Request a sample and discover the recent breakthroughs happening in the Hepatic Tumor pipeline landscape @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatic Tumor Overview
Hepatic tumors, or liver tumors, encompass a wide range of growths that can be either benign or malignant. These tumors originate from different liver cell types, with hepatocellular carcinoma (HCC) being the most common malignant form, arising from hepatocytes. Another significant type is cholangiocarcinoma, which develops in the bile ducts. Additionally, benign liver tumors such as hepatic adenomas, focal nodular hyperplasia, and hemangiomas can occur, though they generally pose less risk than malignant tumors.

The development of hepatic tumors is influenced by various factors, including chronic liver diseases like hepatitis B and C, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Genetic predisposition, exposure to aflatoxins-harmful toxins found in mold-contaminated food-and lifestyle factors such as obesity, smoking, and excessive alcohol consumption also contribute to liver tumor risk. These factors can lead to cellular changes that promote tumor growth, increasing the likelihood of liver cancer over time.

Symptoms of hepatic tumors vary based on their type and progression. Common signs include abdominal pain, unexplained weight loss, nausea, jaundice, and an enlarged liver. Diagnosis involves imaging techniques such as ultrasound, CT scans, or MRI, along with blood tests to assess liver function and tumor markers. Treatment strategies depend on tumor type and stage, with options ranging from surgery, chemotherapy, and radiation therapy to targeted treatments and liver transplantation. Early diagnosis and timely intervention are essential for improving patient outcomes and survival rates.

Find out more about Hepatic Tumor medication @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatic Tumor Treatment Analysis: Drug Profile
MTL CEBPA : MiNA Therapeutics
MTL-CEBPA is an innovative therapy in development for cancer treatment, designed to enhance immune response by restoring C/EBP-α protein levels through RNA activation. It works by reducing immune suppression in myeloid cells via an RNA interference mechanism. Currently, MTL-CEBPA is being evaluated in Phase II clinical trials for the treatment of hepatic tumors.

Amivantamab: Janssen Research & Development, LLC
Amivantamab is a fully human bispecific antibody targeting EGFR and MET, designed to engage immune cells in attacking tumors. It addresses tumors with activating and resistance EGFR mutations, as well as MET mutations and amplifications. Its mechanism of action is based on antibody-dependent cell-mediated cytotoxicity. Currently, Amivantamab is in Phase II clinical trials for the treatment of hepatic tumors.

Fostroxacitabine bralpamide: Medivir AB
Fostroxacitabine bralpamide, developed by Medivir AB, is a small-molecule smart chemotherapy designed to target tumors while minimizing damage to healthy cells selectively. It functions as a nucleotide DNA polymerase inhibitor and is administered orally. Currently, the drug is being evaluated in Phase I/II clinical trials for the treatment of hepatic tumors.

Key Hepatic Tumor Therapies and Companies
• Namodenoson: Can Fite Biopharma
• MTL CEBPA : MiNA Therapeutics
• Amivantamab: Janssen Research & Development, LLC
• Fostroxacitabine bralpamide: Medivir AB
• ETN101: Etnova Therapeutics Corp.

Learn more about the novel and emerging Hepatic Tumor pipeline therapies @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatic Tumor Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Hepatic Tumor Pipeline Report
• Coverage: Global
• Key Hepatic Tumor Companies: Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics., and others.
• Key Hepatic Tumor Pipeline Therapies: Namodenoson, MTL CEBPA, Amivantamab, Fostroxacitabine bralpamide, ETN101, and others.

Dive deep into rich insights for drugs used for Hepatic Tumor treatment; visit @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hepatic Tumor Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hepatic Tumor Pipeline Therapeutics
6. Hepatic Tumor Pipeline: Late-Stage Products (Phase III)
7. Hepatic Tumor Pipeline: Late-Stage Products (Phase III)
8. Hepatic Tumor Pipeline: Mid-Stage Products (Phase II)
9. Hepatic Tumor Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.